Ivacaftor in People with Cystic Fibrosis and a 3849+10kb C→T or D1152H Residual Function Mutation

Rationale: Ivacaftor’s clinical effects in the residual function mutations 3849 + 10kb C→T and D1152H warrant further characterization. Objectives: To evaluate ivacaftor’s effect in people with cystic fibrosis aged ≥6 years with 3849 + 10kb C→T or D1152H residual function mutations and to explore th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerem, Eitan, Cohen-Cymberknoh, Malena, Tsabari, Reuven, Wilschanski, Michael, Reiter, Joel, Shoseyov, David, Gileles-Hillel, Alex, Pugatsch, Thea, Davies, Jane C., Short, Christopher, Saunders, Clare, DeSouza, Cynthia, Sullivan, James C., Doyle, Jamie R., Chandarana, Keval, Kinnman, Nils
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Thoracic Society 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094270/
https://www.ncbi.nlm.nih.gov/pubmed/33095038
http://dx.doi.org/10.1513/AnnalsATS.202006-659OC

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094270/
https://www.ncbi.nlm.nih.gov/pubmed/33095038
http://dx.doi.org/10.1513/AnnalsATS.202006-659OC

Ejemplares similares